Swiss biotech company Relief Therapeutics (RLFT) has filed to uplist its shares to Nasdaq and raise a proposed $20M through a public offering.

While the drug developer didn’t specify in its filing the number or pricing of the shares to be offered, it indicated in its filing fee schedule that it was looking to raise up to $20M.

The company hopes to list its shares on Nasdaq under the symbol RLFT. The company’s shares are already listed on the SIX Swiss Exchange and are traded OTC under the symbol RLFTF. Its American Depositary Shares trade OTC under the symbol RLFTY.

Relief Therapeutics markets specialty treatments for such conditions as chronic wounds, migraine, COVID-19 and Phenylketonuria. Its also working on therapies for urea cycle disorders and certain lung conditions. Many of its products are already marketed in Europe, with the company currently developing a commercial footprint in the US.

For more IPO news, check out SA’s IPO News page.